Breaking News Instant updates and real-time market news.

AQST

Aquestive Therapeutics

$3.07

-0.02 (-0.65%)

07:11
09/30/19
09/30
07:11
09/30/19
07:11

Aquestive Therapeutics announces completion of Phase 1 trial for AQST-108

Aquestive Therapeutics announced the completion of its Phase 1 dose escalation proof-of-concept study in healthy subjects for AQST-108. AQST-108 is an oral sublingual film formulation delivering systemic epinephrine that is in development for the treatment of anaphylaxis using Aquestive's proprietary PharmFilm technologies. Importantly, the data demonstrated that AQST-108: achieved similar ranges of mean values of maximum concentration and time to reach maximum concentration to that reported for injectables EpiPen and Auvi-Q; provided a greater total exposure than that reported for EpiPen and Auvi-Q; had less interpatient variability when compared to degree of variation data reported for EpiPen and Auvi-Q ; was well tolerated, with no study participants discontinuing participation due to an adverse event. Based on the results of this proof-of-concept study, Aquestive is in the process of scheduling a pre-IND meeting with the U.S. FDA.

AQST Aquestive Therapeutics
$3.07

-0.02 (-0.65%)

04/22/19
HCWC
04/22/19
INITIATION
Target $10
HCWC
Buy
Aquestive Therapeutics initiated with a Buy at H.C. Wainwright
H.C. Wainwright analyst Raghuram Selvaraju started Aquestive Therapeutics with a Buy rating and $10 price target. Aquestive is an emerging specialty pharma company optimizing the delivery of existing, well-known medications, says the analyst.
04/22/19
04/22/19
INITIATION

Fly Intel: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. Zoom Video (ZM) initiated with a Sell at Summit Insights. 2. Agenus (AGEN) initiated with a Buy at B. Riley FBR. 3. Aquestive Therapeutics (AQST) initiated with a Buy at H.C. Wainwright. 4. Akamai (AKAM) initiated with a Buy at Needham. 5. Six Flags (SIX) initiated with a Hold at Jefferies. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.
06/10/19
HCWC
06/10/19
NO CHANGE
Target $10
HCWC
Buy
Aquestive Therapeutics recent selloff unwarranted, says H.C. Wainwright
H.C. Wainwright analyst Raghuram Selvaraju believes the recent downward pressure on the stock has been unwarranted, particularly given the "faster-than-previously projected" progress of the Libervant PK study. The analyst reiterates a Buy rating on the shares with a $10 price target.
07/16/19
HCWC
07/16/19
NO CHANGE
Target $12
HCWC
Buy
Aquestive Therapeutics price target raised to $12 from $10 at H.C. Wainwright
H.C. Wainwright analyst Raghuram Selvaraju raised his price target for Aquestive Therapeutics to $12 from $10 saying the company's financial burden is reduced following the completion of its $70M private placement. The refinancing "substantially reduces" Aquestive's quarterly interest payment burden and provides further financial flexibility during the period that may elapse before the company can achieve sustainable profitability, Selvaraju tells investors in a research note. He keeps a Buy rating on the shares.

TODAY'S FREE FLY STORIES

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.